Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Harmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 11/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.97 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.97 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.97 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.97 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.64 |
| ▸ | KLK7 | P49862 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.97 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.97 |
| ▸ | CDK1 | P06493 | 2/20 | 0.97 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.97 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.97 |
| ▸ | CDK2 | P24941 | 2/20 | 0.97 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.97 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Harmine SCHEMBL30726913 | 1.00 | KLK7 (1.00) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL669625 | 0.99 | KLK7 (0.97) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL4907423 | 0.99 | KLK7 (0.97) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL31500130 | 0.99 | KLK7 (0.97) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL292955 | 0.98 | MAOA (1.00) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL9481427 | 0.98 | MAOA (1.00) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL29941920 | 0.98 | MAOA (1.00) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL30510974 | 0.98 | MAOA (1.00) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL29440552 | 0.98 | MAOA (1.00) | KLK7MAOADYRK1AACHECCNB2 | |
| Harmine SCHEMBL16099771 | 0.97 | MAOA (0.97) | KLK7MAOADYRK1AACHECCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233537-A1 | Compositions and Kits of Parts Comprising N,N-Dimethyltryptamine and Harmine and Their Use in Therapy | UNIVERSITY OF ZURICH (CH) | 2023-07-27 | — | — | US | claimed |
| EP-4167992-A1 | COMPOSITIONS AND KITS OF PARTS COMPRISING N,N-DIMETHYLTRYPTAMINE AND HARMINE AND THEIR USE IN THERAPY | University of Zürich (CH) | 2023-04-26 | — | — | EP | claimed |
| CN-115996712-A | Kit of parts and composition comprising N, N-dimethyltryptamine and harmine and use thereof in therapy | 苏黎世大学 | 2023-04-21 | — | — | CN | claimed |
| WO-2021259962-A1 | COMPOSITIONS AND KITS OF PARTS COMPRISING N,N-DIMETHYLTRYPTAMINE AND HARMINE AND THEIR USE IN THERAPY | UNIVERSITY OF ZÜRICH (CH) | 2021-12-30 | — | — | WO | claimed |
| US-9549942-B2 | Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins | Research & Business Foundation Sungkyunkwan University (KR) | 2017-01-24 | — | — | US | claimed |
| CN-1063966-C | Harmel preparation and preparing method thereof | WANG SHIYU (CN) | 2001-04-04 | — | — | CN | claimed |
| CN-1220162-A | Harmel preparation and preparing method thereof | WANG SHIYU (CN) | 1999-06-23 | — | — | CN | claimed |
| CN-1104507-A | Peganum harmala preparation and preparation method thereof | WANG SHIYU (CN) | 1995-07-05 | — | — | CN | claimed |
| EP-4026547-B1 | MEBEVERINE AS SOLUBLE EPOXIDE HYDROLASE INHIBITOR | BANASTHALI VIDYAPITH (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007643-A1 | HIGHLY SOLUBLE FORMULATIONS OF HARMINE | RECONNECT LABS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| CN-119792282-B | Application of harmine in preparing antiviral drugs | 上海交通大学医学院附属瑞金医院 | 2025-11-04 | — | — | CN | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4561527-A2 | HIGHLY SOLUBLE FORMULATIONS OF HARMINE | Reconnect Labs AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-1635846-A2 | SMALL MOLECULE TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | Coley Pharmaceutical GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005007672-A2 | SMALL MOLECULE TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | COLEY PHARMACEUTICAL GMBH (DE) | 2005-01-27 | — | — | WO | disclosed |
| CN-1063966-C | Harmel preparation and preparing method thereof | WANG SHIYU (CN) | 2001-04-04 | — | — | CN | disclosed |
| CN-1220162-A | Harmel preparation and preparing method thereof | WANG SHIYU (CN) | 1999-06-23 | — | — | CN | disclosed |
| CN-1104507-A | Peganum harmala preparation and preparation method thereof | WANG SHIYU (CN) | 1995-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007643-A1 | HIGHLY SOLUBLE FORMULATIONS OF HARMINE | SLC6A2, SLC7A1, DLST | MAOA 160/4885ACHE 1550/4885ADRA2A 710/4885 |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | MAOA 4379/4885ACHE 4643/4885ADRA2A 1099/4885 |
| US-20230233537-A1 | Compositions and Kits of Parts Comprising N,N-Dimethyltryptamine and Harmine and Their Use in Therapy | TPH1, SLC6A4, HNMT | MAOA 19/4885ACHE 438/4885ADRA2A 355/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | MAOA 2167/4885ACHE 1160/4885ADRA2A 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.